sFTX-3.3 is a Ca²⁺ channel antagonist that inhibits P-type and N-type Ca²⁺ channels with IC₅₀ values of approximately 0.24 mM and 0.70 mM, respectively; it reduces the duration of the slow component of presynaptic calcium currents by about 50% and decreases presynaptic sodium currents by approximately 20% at a concentration of 100 μM; it also reduces whole-cell sodium currents in SK-N-SH cells by approximately 15% at 100 μM.